<http://webisa.webdatacommons.org/153104907>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/276568114>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/153104907> .
<http://webisa.webdatacommons.org/prov/389194018>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/153104907> .
<http://webisa.webdatacommons.org/prov/309332800>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/153104907> .
<http://webisa.webdatacommons.org/153104907>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<seekingalpha.com> .
<http://webisa.webdatacommons.org/153104907>	<http://www.w3.org/ns/prov#value>	"Starting with Naglazyme, we continue to find significant numbers of new patients particularly in regions such as Latin America, the Middle East, and Turkey." .